Get the Stockscreener App
0.50
2.19%
-0.0112
After Hours:
.49
-0.01
-2.00%
Vivos Therapeutics Inc stock is traded at $0.50, with a volume of 498.83K.
It is down -2.19% in the last 24 hours and down -16.53% over the past month.
Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.
See More
Previous Close:
$0.5112
Open:
$0.5202
24h Volume:
498.83K
Relative Volume:
0.37
Market Cap:
$6.95M
Revenue:
$19.57M
Net Income/Loss:
$-25.12M
P/E Ratio:
-0.2163
EPS:
-2.3114
Net Cash Flow:
$-19.71M
1W Performance:
-18.53%
1M Performance:
-16.53%
6M Performance:
-74.75%
1Y Performance:
-79.84%
1-Day Range:
$0.45
$0.5202
1-Week Range:
$0.45
$0.6157
52-Week Range:
$0.45
$7.95
Vivos Therapeutics Inc Stock (VVOS) Company Profile
Name
Vivos Therapeutics Inc
Sector
Industry
Phone
(866)908-4867
Address
7921 SOUTHPARK PLAZA,, LITTLETON
Compare VVOS vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VVOS
Vivos Therapeutics Inc
|
0.50 | 6.95M | 19.57M | -25.12M | -19.71M | -2.3114 |
ABT
Abbott Laboratories
|
88.41 | 153.99B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
307.80 | 118.00B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
79.34 | 101.86B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
45.29 | 67.32B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.36 | 50.30B | 6.30B | 1.07B | 1.09B | 1.8406 |
Vivos Therapeutics Inc Stock (VVOS) Latest News
Vivos Therapeutics Inc (VVOS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Vivos Therapeutics Inc (VVOS) Institutional Confidence - TradingKey
Vivos Therapeutics Inc (VVOS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Vivos Therapeutics Inc (VVOS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Vivos Therapeutics Inc (VVOS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Vivos Therapeutics Inc (VVOS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Vivos Therapeutics Inc (VVOS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Vivos Therapeutics Inc (VVOS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Vivos Therapeutics Inc (VVOS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Vivos Therapeutics (NASDAQ: VVOS) outlines proposed tradable rights offering terms - Stock Titan
Vivos Therapeutics Partners with Florida Cardiology Group to Expand Sleep Apnea and Insomnia Treatment for Cardiovascular Patients – Minichart - Minichart
Vivos Therapeutics Forms AIM Florida Sleep Care Venture - TipRanks
Vivos Therapeutics (NASDAQ: VVOS) inks AIM Florida deal with major cardiology group - Stock Titan
Vivos Therapeutics Inc. (VVOS) Q1 2026 Earnings: EPS Misses Estimates as Stock DeclinesLong-Term Guidance - lwvtexas.org
Vivos Therapeutics Plans to File for Proposed Rights Offering - Moomoo
Vivos Therapeutics plans rights offering for shareholders By Investing.com - Investing.com South Africa
Vivos Therapeutics plans rights offering for shareholders - Investing.com
Vivos Therapeutics Announces Intent to File a Registration Statement for a Proposed Rights Offering - The Manila Times
Vivos plans 9‑month tradable rights for shareholders to buy stock - Stock Titan
Vivos Therapeutics Announces Key Collaboration Agreement with Multi-Location Florida Cardiology Group to Extend Much Needed Sleep Apnea and Insomnia Diagnosis and Treatment to Cardiovascular Patients - The Manila Times
Vivos Therapeutics Enters Collaboration With Florida Firm to Treat Cardiovascular Patients - Moomoo
VVOS: Capital-light, scalable sleep apnea treatment model targets rapid, profitable national expansion - TradingView
VVOS: Rapidly scaling sleep apnea treatment with high margins and unique FDA-cleared devices - TradingView
Vivos Therapeutics, Inc. to Present at The Small Cap Showcase & WTR Insights on June 9, 2026 - Quiver Quantitative
Vivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026 - The Manila Times
Vivos Therapeutics Announces $4.5 Million Debt-to-Equity Exchange Agreement to Support Nasdaq Listing and Strengthen Financial Position – Minichart - Minichart
Vivos Therapeutics Restructures Debt to Support Nasdaq Compliance - TipRanks
Vivos Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
[8-K] Vivos Therapeutics, Inc. Reports Material Event - Stock Titan
Vivos Therapeutics agrees to debt-to-equity exchange with lender By Investing.com - Investing.com South Africa
6/5/2026 Market UpdateWinners: NOTV, STI, BGMSLosers: BIGGQ, NUWE, CYPHS&P 500: -2.6% - Trefis
Vivos Therapeutics Shares Surge After $4.5 Million Debt Conversion Fuels Nasdaq Optimism - TechStock²
Vivos Therapeutics (VVOS) Stock: Debt Exchange Plan Fuels Investor Optimism - parameter.io
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Vivos Therapeutics agrees to debt-to-equity exchange with lender - Investing.com
Vivos Therapeutics Announces Debt Exchange Agreement with Streeterville Capital to Strengthen Financial Position - Quiver Quantitative
Vivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq Listing - marketscreener.com
Press Release: Vivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million From Streeterville Capital to Support Continued Nasdaq Listing - Moomoo
Vivos Inc. (OTCQB: RDGL) submits Early Feasibility Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) for RadioGel® Precision Radionuclide Therapy™ - Yahoo Finance
CrowdStrike To Surge Nearly 25%? Here Are 10 Notable Analyst Calls From Thursday - Benzinga
Vivos Therapeutics (VVOS) Gains 4.5% as Stock Tests Key Resistance at $0.73Growth Stock Picks - The Legal Advocate
VVOS Should I Buy - Intellectia AI
Vivos Therapeutics Inc (VVOS) Q1 2026 Earnings Call Highlights: Revenue Surges Amid Strategic Shifts By GuruFocus - Investing.com Canada
VVOS - Finviz
Vivos Therapeutics Balances Rapid Growth With Cash Strain - The Globe and Mail
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q1 2026 Earnings Call Transcript - Insider Monkey
Vivos Therapeutics Earnings Call: Growth Meets Cash Strain - The Globe and Mail
Vivos Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Update - The Manila Times
Vivos Therapeutics, Inc. 1Q 2026: Revenue $5.14M, EPS $(0.52) — 10-Q Summary - TradingView
Vivos Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Vivos Therapeutics (NASDAQ: VVOS) Q1 2026 loss and going concern risk - Stock Titan
Vivos Therapeutics Inc Stock (VVOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):